2020 Q1 Form 10-Q Financial Statement
#000156459020021342 Filed on May 05, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $24.64M | $21.97M |
| YoY Change | 12.15% | 61.97% |
| Cost Of Revenue | $8.320M | $8.430M |
| YoY Change | -1.3% | 15.01% |
| Gross Profit | $16.32M | $13.53M |
| YoY Change | 20.62% | 117.04% |
| Gross Profit Margin | 66.23% | 61.58% |
| Selling, General & Admin | $15.91M | $16.16M |
| YoY Change | -1.53% | 18.77% |
| % of Gross Profit | 97.51% | 119.45% |
| Research & Development | $15.81M | $13.44M |
| YoY Change | 17.63% | 42.42% |
| % of Gross Profit | 96.88% | 99.33% |
| Depreciation & Amortization | $706.0K | $376.0K |
| YoY Change | 87.77% | -8.96% |
| % of Gross Profit | 4.33% | 2.78% |
| Operating Expenses | $31.72M | $29.60M |
| YoY Change | 7.17% | 28.45% |
| Operating Profit | -$15.40M | -$16.07M |
| YoY Change | -4.16% | 20.34% |
| Interest Expense | -$1.160M | -$3.090M |
| YoY Change | -62.46% | -437.7% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $150.0K | $420.0K |
| YoY Change | -64.29% | -188.24% |
| Pretax Income | -$16.41M | -$18.73M |
| YoY Change | -12.39% | 35.42% |
| Income Tax | $57.00K | $60.00K |
| % Of Pretax Income | ||
| Net Earnings | -$16.47M | -$18.79M |
| YoY Change | -12.38% | 35.34% |
| Net Earnings / Revenue | -66.83% | -85.53% |
| Basic Earnings Per Share | -$0.14 | |
| Diluted Earnings Per Share | -$104.6K | -$0.14 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 162.2M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $133.1M | $100.4M |
| YoY Change | 32.57% | -5.19% |
| Cash & Equivalents | $36.12M | $31.73M |
| Short-Term Investments | $99.40M | $71.40M |
| Other Short-Term Assets | $5.400M | $5.000M |
| YoY Change | 8.0% | 16.28% |
| Inventory | $21.68M | $15.80M |
| Prepaid Expenses | ||
| Receivables | $18.20M | $13.80M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $178.3M | $134.9M |
| YoY Change | 32.17% | 0.82% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $28.70M | $31.70M |
| YoY Change | -9.46% | 1485.0% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $6.900M | $7.700M |
| YoY Change | -10.39% | 11.59% |
| Total Long-Term Assets | $37.10M | $41.00M |
| YoY Change | -9.51% | 286.79% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $178.3M | $134.9M |
| Total Long-Term Assets | $37.10M | $41.00M |
| Total Assets | $215.4M | $175.9M |
| YoY Change | 22.46% | 21.81% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $20.20M | $20.90M |
| YoY Change | -3.35% | 86.61% |
| Accrued Expenses | $17.20M | $20.00M |
| YoY Change | -14.01% | 106.19% |
| Deferred Revenue | $763.0K | |
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $4.800M | $0.00 |
| YoY Change | -100.0% | |
| Total Short-Term Liabilities | $45.10M | $47.59M |
| YoY Change | -5.24% | 100.82% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $39.50M | $39.40M |
| YoY Change | 0.25% | 38.73% |
| Other Long-Term Liabilities | $18.40M | $88.00K |
| YoY Change | 20809.09% | -98.71% |
| Total Long-Term Liabilities | $57.90M | $88.00K |
| YoY Change | 65695.45% | -99.75% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $45.10M | $47.59M |
| Total Long-Term Liabilities | $57.90M | $88.00K |
| Total Liabilities | $103.0M | $106.4M |
| YoY Change | -3.22% | 81.0% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$797.7M | |
| YoY Change | ||
| Common Stock | $867.2M | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $112.4M | $69.50M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $215.4M | $175.9M |
| YoY Change | 22.44% | 21.83% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$16.47M | -$18.79M |
| YoY Change | -12.38% | 35.34% |
| Depreciation, Depletion And Amortization | $706.0K | $376.0K |
| YoY Change | 87.77% | -8.96% |
| Cash From Operating Activities | -$19.80M | -$22.18M |
| YoY Change | -10.71% | 114.8% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $452.0K | $3.315M |
| YoY Change | -86.37% | 6275.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$49.73M | $16.50M |
| YoY Change | -401.39% | -136.92% |
| Cash From Investing Activities | -$50.19M | $13.19M |
| YoY Change | -480.62% | -129.47% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $67.70M | |
| YoY Change | ||
| Debt Paid & Issued, Net | $31.01M | |
| YoY Change | 96806.25% | |
| Cash From Financing Activities | 68.68M | 9.133M |
| YoY Change | 652.04% | -84.47% |
| NET CHANGE | ||
| Cash From Operating Activities | -19.80M | -22.18M |
| Cash From Investing Activities | -50.19M | 13.19M |
| Cash From Financing Activities | 68.68M | 9.133M |
| Net Change In Cash | -1.303M | 140.0K |
| YoY Change | -1030.71% | -96.28% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$19.80M | -$22.18M |
| Capital Expenditures | $452.0K | $3.315M |
| Free Cash Flow | -$20.25M | -$25.49M |
| YoY Change | -20.55% | 145.67% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q1 | us-gaap |
Revenue Practical Expedient Remaining Performance Obligation
RevenuePracticalExpedientRemainingPerformanceObligation
|
true | |
| CY2020Q1 | cers |
Product Warranty Term
ProductWarrantyTerm
|
P1Y | |
| CY2019Q1 | cers |
Gross Profit On Product Revenue
GrossProfitOnProductRevenue
|
9072000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1283000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2226000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-1119000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2308000 | |
| CY2020Q1 | cers |
Increase Decrease In Accrued Liabilities And Other Noncurrent Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities
|
-4356000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
39433000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
68684000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1303000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
37421000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
31587000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
36118000 | |
| CY2020Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2020Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22145000 | |
| CY2020Q1 | us-gaap |
Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
|
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Guarantee and Indemnification Arrangements</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company’s technology infringes the intellectual property rights of a third-party or claims that the sale or use of the Company’s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally provides for a <span style="-sec-ix-hidden:F_000318">one-year</span> warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has not experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at March 31, 2020 and December 31, 2019.</p> | |
| CY2020Q1 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
0 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
364000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
110159000 | |
| CY2020Q1 | cers |
Gross Profit On Product Revenue
GrossProfitOnProductRevenue
|
10291000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
15810000 | |
| CY2019Q1 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
13440000 | |
| CY2020Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
15913000 | |
| CY2019Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
16161000 | |
| CY2020Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-223000 | |
| CY2019Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-162000 | |
| CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
57000 | |
| CY2019Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
60000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16466000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18792000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.10 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.14 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
157405000 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
137108000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-237000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
211000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-16703000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-18581000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
57052000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
67112000 | |
| CY2020Q1 | cers |
Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
|
1193000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3754000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-237000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
112408000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
84519000 | |
| CY2019Q1 | cers |
Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
|
684000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2878000 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
376000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3754000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2878000 | |
| CY2020Q1 | cers |
Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
|
-300000 | |
| CY2019Q1 | cers |
Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
|
-353000 | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
|
-267000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18792000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
69500000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-16466000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-18792000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
706000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
1193000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
710000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
67695000 | |
| CY2020Q1 | us-gaap |
Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
|
204000 | |
| CY2019Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
31010000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
9133000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
140000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-22178000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
452000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3315000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
68520000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
1000000 | |
| CY2020Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
18787000 | |
| CY2019Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
17500000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-50185000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
13185000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
31727000 | |
| CY2020Q1 | cers |
Non Cash Interest Expense
NonCashInterestExpense
|
119000 | |
| CY2019Q1 | cers |
Non Cash Interest Expense
NonCashInterestExpense
|
197000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
5004000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2286000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-2165000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
2597000 | |
| CY2019Q1 | cers |
Increase Decrease In Accrued Liabilities And Other Noncurrent Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities
|
-4809000 | |
| CY2019Q1 | cers |
Increase Decrease In Manufacturing And Development Payment Liability
IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability
|
-118000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
572000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
265000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19802000 | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to the nature and timing of satisfaction of performance obligations, the timing when the customer obtains control of products or services, the standalone selling price (“SSP”) of performance obligations, variable consideration, accounts receivable, inventory reserves, fair values of investments, the allowance for credit losses, stock-based compensation, intangible assets and goodwill, useful lives of intangible assets and property and equipment, income taxes, accrued liabilities, and incremental borrowing rate, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</p> | |
| CY2019Q4 | us-gaap |
Contract With Customer Asset Net
ContractWithCustomerAssetNet
|
0 | |
| CY2020Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
300000 | |
| CY2019Q4 | cers |
Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
|
3 | |
| CY2020Q1 | cers |
Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
|
3 | |
| CY2020Q1 | cers |
Work In Process Inventory Life Period
WorkInProcessInventoryLifePeriod
|
P1Y | |
| CY2020Q1 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
200000 | |
| CY2019Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
100000 | |
| CY2020Q1 | us-gaap |
Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
|
The Company invoices its customers based upon the terms in the contracts, which generally requires payment 30 to 60 days from the date of invoice. | |
| CY2020Q1 | us-gaap |
Contract With Customer Asset Net
ContractWithCustomerAssetNet
|
0 | |
| CY2020Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
200000 | |
| CY2019Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2900000 | |
| CY2020Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company’s investment policy, substantially all of the Company’s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company’s investments carry high credit quality ratings, which is in accordance with its investment policy. At March 31, 2020, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company’s cash equivalents and short-term investments.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to trade receivables exist. On a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company establishes an allowance for doubtful accounts against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations as a component of selling, general and administrative expenses.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had three customers that accounted for more than 10% of the Company’s outstanding trade receivables at March 31, 2020 and December 31, 2019, respectively. These customers cumulatively represented approximately 58% and 56% of the Company’s outstanding trade receivables at March 31, 2020 and December 31, 2019, respectively. To date, the Company has not experienced collection difficulties from these customers.</p> | |
| CY2020Q1 | us-gaap |
Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
|
P10Y | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1900000 | |
| CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1900000 | |
| CY2020Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2020Q1 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | |
| CY2019Q1 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
19902000 | |
| CY2019Q4 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
0 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
110282000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
487000 | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
110159000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
59478000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
114000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
59592000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
43907000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
55811000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
55594000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
15656000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
15685000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
110282000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
59478000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
59592000 | |
| CY2019Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
0 | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | |
| CY2019Q1 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
|
300000 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
|
0 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
|
0 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
110159000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
59592000 | |
| CY2020Q1 | us-gaap |
Inventory Net
InventoryNet
|
21684000 | |
| CY2019Q4 | us-gaap |
Inventory Net
InventoryNet
|
19490000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
12703000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
3489000 | |
| CY2020Q1 | cers |
Accrued Development Costs Current
AccruedDevelopmentCostsCurrent
|
1369000 | |
| CY2019Q4 | cers |
Accrued Development Costs Current
AccruedDevelopmentCostsCurrent
|
1468000 | |
| CY2020Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
17198000 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
20951000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
16053000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
30372000 | |
| CY2020Q1 | cers |
Minimum Term Of Non Cancelable Operating Leases
MinimumTermOfNonCancelableOperatingLeases
|
P1Y | |
| CY2020Q1 | cers |
Expiration Of Non Cancelable Operating Leases Maximum Year
ExpirationOfNonCancelableOperatingLeasesMaximumYear
|
2030 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
964000 | |
| CY2020Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
265000 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P9Y | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.089 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
2443000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3450000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2927000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
2788000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
2711000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
10616000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
19756000 | |
| CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
800000 | |
| CY2019Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
500000 | |
| CY2020Q1 | us-gaap |
Lessor Operating Lease Lease Not Yet Commenced Description
LessorOperatingLeaseLeaseNotYetCommencedDescription
|
the Company had no leases that have not yet commenced. | |
| CY2020Q1 | cers |
Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
|
8100000 | |
| CY2019Q1 | cers |
Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
|
7800000 | |
| CY2020Q1 | cers |
Accrual For Manufacturing Of Entity Products
AccrualForManufacturingOfEntityProducts
|
8262000 | |
| CY2019Q4 | cers |
Accrual For Manufacturing Of Entity Products
AccrualForManufacturingOfEntityProducts
|
8470000 | |
| CY2020Q1 | us-gaap |
Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
|
1631000 | |
| CY2019Q4 | us-gaap |
Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
|
1796000 | |
| CY2020Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 |
